baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Agios Pharmaceuticals/ US00847X1046 /

2024-06-04 9:59:55 PM	Chg. +3.45	Volume	Bid-	Ask-	High	Low
47.28USD	+7.87%	68,337 Turnover: 3.15 mill.	-Bid Size: -	-Ask Size: -	47.73	43.81

GlobeNewswire 06-03 Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary End...

GlobeNewswire 05-30 Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

GlobeNewswire 05-28 Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million

GlobeNewswire 05-28 Agios Announces $905 Million Purchase Agreement for Vorasidenib Royalty

GlobeNewswire 05-14 Agios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European...

GlobeNewswire 05-06 Agios to Present at the BofA Securities 2024 Health Care Conference on May 16, 2024

GlobeNewswire 05-03 Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024

GlobeNewswire 05-02 Agios Reports Business Highlights and First Quarter 2024 Financial Results

GlobeNewswire 04-18 Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024

GlobeNewswire 04-09 Agios Publishes 2024 Environmental, Social and Governance (ESG) Report

GlobeNewswire 03-05 Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024

GlobeNewswire 02-22 Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024

GlobeNewswire 02-15 OnKure Announces the Appointment of Samuel Agresta, M.D., as Chief Medical Officer

GlobeNewswire 02-15 Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

GlobeNewswire 02-02 Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 1...

GlobeNewswire 01-08 Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio

GlobeNewswire 01-03 Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endp...

GlobeNewswire 01-02 Agios to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024

GlobeNewswire 2023-12-10 Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Dis...

GlobeNewswire 2023-11-20 Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in...

GlobeNewswire 2023-11-02 Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood Disorder...

GlobeNewswire 2023-11-02 Agios Reports Business Highlights and Third Quarter 2023 Financial Results

GlobeNewswire 2023-10-19 Agios to Webcast Conference Call of Third Quarter 2023 Financial Results on Nov. 2, 2023

GlobeNewswire 2023-09-19 Marketing and Finance Leaders Seek Collaboration to Make Smarter Investments, Says CMO Council and K...

GlobeNewswire 2023-09-08 Regeneron Announces Updates to Board of Directors

Agios Pharmaceuticals/ US00847X1046 /

If you wish to receive reply to your feedback, please provide your email address.